INFI News and Press, Infinity Pharmaceuticals Inc. From 12/08/20

Gainers: Curis (CRIS) +335%.Lexicon Pharmaceuticals (LXRX) +97%.Mammoth Energy Services (TUSK) +61%.NeuroMetrix (NURO) +49%.Stitch Fix (SFIX) +45%.IGM Biosciences (IGMS) +38%.Blonder Tongue Laboratories (BDR) +26%.Infinity Pharmaceuticals (INFI) +25%.KLX Energy Services (KLXE) +24%....

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) which will be presented during the San Antonio Breast...

Recent results pleased analysts. The company's relationship with various Big Pharma companies will be key to  future revenues and to the stock price. The market in general sees great potential for pharma companies working on cancer developments. Further key product test d...

Gainers: Phoenix Tree (DNK) +65%.Lexicon Pharmaceuticals (LXRX) +43%.Riot Blockchain (RIOT) +40%.Zomedica Pharmaceuticals (ZOM) +33%.Miragen Therapeutics (MGEN) +28%.AXT (AXTI) +27%.Glory Star New Media Group (GSMG) +26%.Yunhong CTI (CTIB) +23%.Kandi Technologies (KNDI) +22%.Se...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held virtually, Decembe...

Infinity Pharmaceuticals, Inc. (INFI) Q3 2020 Earnings Conference Call November 09, 2020, 16:30 ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman & CEO Brian Schwartz - Consulting Chief Physician Lawrence Bloch - President & Treasurer Con...

Infinity Pharmaceuticals (INFI): Q3 GAAP EPS of -$0.16 misses by $0.01.Revenue of $0.5M (+47.1% Y/Y) beats by $0.29M.Net Loss: Infinity expects net loss for 2020 to range from $35 million to $45 million.Cash and Investments: Infinity expects to end 2020 with a year-end cash, cash equivalents ...

– MARIO-275 IDMC Determined that Risk/Benefit for Patients Warrants Resumption of Enrollment; Infinity to Determine Next Steps by Year End – – MARIO-3 Encouraging Data in Front-Line Triple Negative Breast Cancer Patients to be Presented at San Anto...

– Data from melanoma and SCCHN cohorts demonstrate eganelisib was well tolerated in combination with Opdivo ® – - Translational data supports on-mechanism immune modulation - - Clinical activity in patients with two or fewer prior lines of therap...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), will host a conference call on November 9, 2020 at ...